Vinu Krishnan

Principal Research Scientist @abbvie I @Harvard Fellow I @UDengineering PhD I @UAkron BS/MS

[Vinu Krishnan @DrKrishtweets]

Hear me pitch ⁦⁦@MIT⁩⁦@Harvard⁩ Ideation 2019. It’s tonight Mon Apr 22, 2019, at 6 PM and Prof. Bob Langer is the keynote speaker! #Pharmaceutical #entrepreneurs @SMitragotri⁩ ⁦⁦⁦⁦⁦@hseas ⁦@wyssinstitute⁩ ⁦@thebiotechclub⁩ https://t.co/AS8gjvom8D

[Vinu Krishnan @DrKrishtweets]

Intellia once again leads the way with the first-ever in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development!!!

Proud of the entire team on this achievement. #CRISPR #OneIntellia #ATTR

[Intellia Therapeutics @intelliatx]

#ATTR News: @US_FDA cleared Intellia’s NTLA-2001 IND application to enter late-stage clinical development for the treatment of #transthyretinamyloidosis with cardiomyopathy: https://t.co/q1m2h9SANH

NTLA-2001 is the first-ever investigational in vivo therapy cleared by FDA to enter a Phase 3 trial. #CRISPR #GeneEditing

[Gene Investing w/Anthony 🧬 @GeneInvesting]

Let’s GO!!!

➡️The word “hold” is not in Intellia’s vocabulary!

Intellia Announces FDA Clearance of IND Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

$NTLA $VERV $BEAM https://t.co/zzi4lCo2RW

[Lucas Harrington @CRISPR_LuCas]

Congrats to @intelliatx and everyone that has played a part in the advancement of CRISPR to get it to this point! This is a significant milestone for the entire gene editing field🎉 https://t.co/XfglmnSZjU

[Intellia Therapeutics @intelliatx]

#HAE News: Intellia has been awarded the Innovation Passport in the U.K. by @MHRAgovuk for NTLA-2002, the company’s investigational #genomeediting treatment for #hereditaryangioedema. Learn more: https://t.co/6iM67LbdXB

[Vinu Krishnan @DrKrishtweets]

@intelliatx we drive the future of medicine and the BEST is YET to COME!!!

[Intellia Therapeutics @intelliatx]

Intellia CEO, John Leonard, reflects on Intellia’s recent growth, accomplishments and the journey that lies ahead: https://t.co/WBZAVCfVZA #CRISPR #genomeediting #OneIntellia

[Alliance for Regenerative Medicine (ARM) @alliancerm]

“A big part of this is education.”

@intelliatx Chief Business Officer Derek Hicks emphasizes that the cell and gene sector needs to better educate regulators and the public to support systems for successful CMC. #CGSOTI23

[Intellia Therapeutics @intelliatx]

$NTLA News: Intellia highlights its recent accomplishments, strategic priorities and key anticipated 2023 milestones: https://t.co/ofbDHaeUxy #CRISPR #genomeediting

[FIFA World Cup @FIFAWorldCup]

The best #FIFAWorldCup Final ever.

[Fyodor Urnov @UrnovFyodor]

CRISPR has delivered on a key aspect of its promise as a platform technology: going from disease 1 to disease 2 requires changing only 20 nt in an RNA.
This is exactly what @intelliatx just did: the HAE data look as good as the TTR ones.
YAY+BRAVO!
https://t.co/kzyze2P2Dy

[Laura Sepp-Lorenzino @LauraSepplore]

Today’s #HAE and #ATTR data support the modularity of Intellia’s industry-leading #genomeediting platform. Incredibly proud to be part of #OneIntellia!

[Intellia Therapeutics @intelliatx]

$NTLA announced today the @US_FDA has granted orphan drug designation for our in vivo #CRISPR/Cas9 genome editing candidate, NTLA-2002, for the treatment of hereditary angioedema (#HAE). Learn more: https://t.co/lNy64hG13W

[Laura Sepp-Lorenzino @LauraSepplore]

Congratulations @intelliatx! Learn more about NTLA-2002 on our website and at an upcoming presentation at the 2022 Bradykinin Symposium
https://t.co/QpLALzJmEP
https://t.co/psTSIVFJtQ
#HAE #CRISPR #ONEintellia

[Intellia Therapeutics @intelliatx]

$NTLA announces upcoming date for the presentation of interim clinical data for our second systemically administered in vivo #CRISPR candidate: https://t.co/SZQQXWzbKT

[Vinu Krishnan @DrKrishtweets]

@HarmitMalik @netflix or more like a 007 wannabe 😜

[Vinu Krishnan @DrKrishtweets]

@ygreenst @Alnylam Congratulations @Alnylam 🎊🎈🍾🎉 ! Exciting times for #RNAitherapeutics!

[Dr. Yvonne Greenstreet @ygreenst]

I’m so proud of our team, and today’s APOLLO-B announcement which represents the next step in @Alnylam’s journey both in building our TTR franchise and toward achieving our P5x25 corporate vision of becoming a leading biopharma company. #RNAitherapeutics #siRNA

[Vinu Krishnan @DrKrishtweets]

@jay_jayoungkim @UNTHSC_Pharmacy Congratulations @jay_jayoungkim 🍾🎈🎉🎊! Can't wait to see your lab advance the frontiers of precision gene therapy #newPI #GeneTherapy #nanomedicine

[Vinu Krishnan @DrKrishtweets]

OMG!!! 😱 chaotic British Grand Prix is about to get a chaotic sprint finish #BritishGP

[Vinu Krishnan @DrKrishtweets]

@_taosun_ @Northeastern @NUBioE1 @cilsinstitute Woohoo 🥳 Congratulations @_taosun_ 🎉🎈🍾 ! Great to know you will still be in Boston. Looking forward to meeting you and your lab in the coming years

[Tao Sun @_taosun_]

This young PI needs to get LOS from Big Names ABCDEFG (but without time efforts bc the budget is limited 🤏)